Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Chemiluminescence Imaging

By Drug Discovery Trends Editor | July 15, 2009

SysgeneSyngene, a manufacturer of image analysis solutions, announced that its G:BOX chemiluminescence imaging system is now being used by scientists at Edinburgh Napier University in Edinburgh, Scotland  to accurately determine the effectiveness of novel anti-cancer therapies.

Researchers in the School of Life Sciences at Edinburgh Napier University are using the G:BOX chemiluminescence imaging system to image agarose gels of DNA stained with Ethidium Bromide to determine the effects that new anti-topoisomerase compounds have on topoisomerase action during the cell cycle. The researchers are also using the system to image gelatin zymograms to discover the effects that compounds have on the modulation of matrix metalloproteinases. The scientists believe their research could help develop novel drugs to treat a variety of cancers.

Dr David Mincher, Reader in Experimental Chemotherapy at Edinburgh Napier explained:” In recent years, the action of topoisomerases and matrix metalloproteinases have been implicated in many cancers. Therefore, we are looking at a number of New Chemical Entities and pro-drugs which target these proteins but to determine the efficacy of these compounds we have to be able to precisely quantify their effects on the expression of DNA or proteins. Since we need high levels of accuracy and reproducibility in our results we installed a G:BOX imaging system just over a year ago to work alongside our other Syngene image analyzer and the new system has been absolutely invaluable for this project.”

Laura Sullivan, Syngene’s Divisional Manager in the UK added: “We are delighted Edinburgh Napier University has chosen to install another Syngene system and to see how much the G:BOX system is contributing to this exciting research. The work at Edinburgh Napier is an excellent endorsement of the system’s ability to rapidly produce and analyze images of applications as diverse as 1D gels, zymograms and autoradiograms and means G:BOX chemiluminescence imaging systems can be confidently used in many drug discovery programs where accurately quantifying DNA and protein amounts is critical.”

Syngene


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE